It’s A Great Day To Buy Array BioPharma Inc. (ARRY) on the Dip

It’s A Great Day To Buy Array BioPharma Inc. (ARRY) on the Dip

It’s A Great Day To Buy Array BioPharma Inc. (ARRY) on the Dip

Array BioPharma Inc. (NASDAQ:ARRY) stock is presently standing at about $8.65 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 9 analysts covering the company is $13.00, which suggests the stock could still rise over 33 percent. The highest analyst price target is $15.00, which implies a rally of 27 percent. And a quick view of analyst notes show that 4 are rating the stock a buy while 3 rate ARRY a strong buy. There are 2 equity research firms advocating a Hold and 0 consider it Sell.

JP Morgan analysts provided their view on Array BioPharma Inc. (NASDAQ:ARRY) recently. The rating firm issued a Overweight rating to this company in a research note released on May 03, 2017. JP Morgan analysts disclosed their opinion on Array BioPharma Inc. (NASDAQ:ARRY) recently. The rating firm gave a Neutral rating to this stock in a research note published on Feb 03, 2017. According to a research note disclosed on Jan 30, 2017, analysts at Leerink Partners have lowered their rating on these shares from Outperform to Mkt Perform.

Array BioPharma Inc. (NASDAQ:ARRY) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its Director LEFKOFF KYLE Sold 6,585 company shares for 401,400, in a transaction on Mar 31. Following the transaction, the Director is left with a stake of 45,000 shares, currently valued at $389,250. Meanwhile, Director BAUM CHARLES M sold 5,000 shares worth $231,750, through a transaction dated Mar 28. Following the completion of the transaction, the insider is left with a stake of 25,000 shares, amounting $216,250. ARRY 10% Owner Redmile Group, LLC also sold 16,658,072 shares, at a stock price of $6.36. This transaction occurred on Sep 28 totals $15,852,796. After this transaction, the insider’s stake stands at 2,492,578 shares, with a market value of $21,560,800.

Executives hold 1.63 percent of the stock. FMR LLC is one of the biggest insider owners in Array BioPharma Inc. (NASDAQ:ARRY), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 23,275,836 shares which have current market value of around $201,335,981.VANGUARD GROUP INC is another major inside shareholder in the company. The insider owns 16,993,415 shares as of 03/31/2017, currently worth $146,993,040. ORBIMED ADVISORS LLC is ranked as third insider holder of the stock. This insider holds 14,182,900 shares with a market value around $122,682,085 as of recent close.

Array BioPharma Inc. (NASDAQ:ARRY) Earnings Outlook

In Array BioPharma Inc. (NASDAQ:ARRY)’s latest quarter, EPS moved to $-0.21 from $-0.14 in preceding quarter and revenues reached at $33.28M compared to $44.52M. Analysts had expected Array BioPharma Inc. (NASDAQ:ARRY) to post net income of about $-0.16 per share on $36.99M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.31 to $0.08. That is compared with the $-0.17 in EPS it reported during the same period a year ago.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.